Updated:
Byers Capital
Brook Byers runs Byers Capital, a Menlo Park family office deploying KPCB wealth into early-stage life science companies like CRISPR Therapeutics.
Byers Capital
Byers Capital represents the private investment office of the Brook Byers family, whose wealth stems from a nearly 50-year partnership at Kleiner Perkins Caufield & Byers. Brook Byers joined the pioneering venture firm in 1977 and structured early financings for over 60 companies that later went public or were acquired. The family office launches from a record that includes early roles in Genentech, Idec Pharmaceuticals, and Alnylam Pharmaceuticals, positioning it as a continuation of a specific biotech-focused archetype: the venture-scientist-turned-principal who can underwrite platform technologies from the lab bench to the clinic. The firm invests from seed through growth equity, concentrating on life sciences, digital health, and applied technology. Its direct deal posture favors founding-stage commitments alongside leading venture platforms, placing it in the tight-knit network of early-stage biotech syndicate leads. Known portfolio companies include CRISPR Therapeutics, which went public in 2016, and Relay Therapeutics, a clinical-stage precision medicine company that listed in 2020. The office also examines computational biology, climate-focused biotechnology, and enterprise software investments initiated by the next generation of the Byers family, particularly Sean Byers. Byers Capital operates with a lean structure typical of family offices built around a high-profile investment career. Sean Byers co-manages investments with his father, specializing in enterprise technology and consumer health startups. The office has made investments in companies like Standard Cognition and K Health, reflecting the second generation's expansion beyond pure biotech into health delivery and AI applications. Stanford University and UCSF, both in the Bay Area ecosystem that produced Brook Byers's firm-building career, remain persistent sources of deal origination. The office's structural differentiator is the multi-generational effect: it combines the clinical trial and boardroom heft of a KPCB legend with the adjacent internet and consumer-health instincts of younger family members. This creates an investment entity that behaves like a super-angel syndicate on one track and a stage-agnostic biotech backer on the other — a hybrid that few family offices without multi-decade venture firm roots can replicate.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Principals
Brook Byers
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Byers Capital?
Brook Byers serves as the managing partner, with his son Sean Byers playing an active co-investing role. Brook Byers built his career as a general partner at Kleiner Perkins Caufield & Byers, where he focused on life sciences for over 40 years. Sean Byers sources and underwrites technology and consumer-facing health investments, reflecting a deliberate transfer of generational investment authority.
Where does the underlying wealth come from?
The family's wealth originates from Brook Byers's career at Kleiner Perkins, which he joined in 1977. Over four decades, he was instrumental in founding and funding over 60 life science companies that achieved public listings or acquisitions, spanning from Genentech in the early 1980s to genomic medicine companies in the 2010s. Carried interest and direct equity from those outcomes form the asset base.
How does Byers Capital source proprietary deal flow?
Sourcing relies on Brook Byers's network built over 45 years in venture capital, which includes deep ties to Stanford University, UCSF, and academic research commercialization offices in the Bay Area. The office often enters deals shared by peer venture firms — particularly life science specialists — and leans heavily on the founder relationships and scientific advisory board connections Byers developed at Kleiner Perkins.
Does Byers Capital take board seats in portfolio companies?
Yes, Brook Byers has historically taken board positions in select portfolio companies, a practice he carried over from his Kleiner Perkins tenure. In the family office context, board service is likely selective and reserved for companies where the exposure is large or the scientific domain aligns closely with his expertise, though specific current board roles are not systematically disclosed.
Is Byers Capital structured as a single family office or does it manage outside capital?
Byers Capital functions as a single family office managing the capital of the Brook Byers family. It does not register as an investment advisor or openly solicit third-party capital. The office's deployment pattern — unconstrained, stage-agnostic, and focused on fields where the family holds a knowledge edge — conforms to the structure of a pure family vehicle.
What investment stages and check sizes does Byers Capital target?
The office invests from seed to growth equity, often as a first-institutional-check alongside syndicated venture rounds. Byers Capital has entered companies at the Series A stage in synthetic biology and CRISPR platforms and has participated in later rounds for digital health companies like K Health. AUM is not disclosed, which is characteristic of a family office that can size checks opportunistically against its balance sheet rather than against fund-level constraints.
How is Byers Capital related to Kleiner Perkins?
Byers Capital has no formal affiliation with Kleiner Perkins Caufield & Byers. The link is biographical: Brook Byers spent his career as a GP at Kleiner Perkins, and the family office invests proceeds earned during that tenure. The two entities may occasionally co-invest, but there is no structural or economic relationship.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: